Research Analysts Set Expectations for ELVN FY2025 Earnings

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Research analysts at Lifesci Capital lifted their FY2025 EPS estimates for Enliven Therapeutics in a research note issued on Monday, March 17th. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings of ($2.54) per share for the year, up from their previous forecast of ($2.57). The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter.

Separately, BTIG Research assumed coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price target for the company. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $20.92 on Wednesday. The company has a fifty day moving average of $21.32 and a 200-day moving average of $23.76. The company has a market capitalization of $1.03 billion, a PE ratio of -11.01 and a beta of 1.04. Enliven Therapeutics has a 52-week low of $15.96 and a 52-week high of $30.03.

Insider Transactions at Enliven Therapeutics

In related news, COO Anish Patel sold 6,667 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the completion of the sale, the chief operating officer now directly owns 329,977 shares in the company, valued at $7,236,395.61. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Benjamin Hohl sold 3,350 shares of the stock in a transaction on Friday, December 27th. The shares were sold at an average price of $22.15, for a total value of $74,202.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,284 shares of company stock worth $1,352,750. Corporate insiders own 29.20% of the company’s stock.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ELVN. Quest Partners LLC increased its holdings in Enliven Therapeutics by 1,226.4% in the third quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock valued at $539,000 after purchasing an additional 19,525 shares during the period. First Turn Management LLC increased its holdings in Enliven Therapeutics by 29.5% in the third quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after purchasing an additional 121,849 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Enliven Therapeutics by 10.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock valued at $6,520,000 after purchasing an additional 24,043 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Enliven Therapeutics by 25.6% in the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after purchasing an additional 3,518 shares during the period. Finally, FMR LLC increased its holdings in Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after purchasing an additional 601,611 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.